Vericel Corp (VCEL)
56.71
-0.55
(-0.96%)
USD |
NASDAQ |
Nov 21, 16:00
56.72
+0.01
(+0.02%)
After-Hours: 20:00
Vericel Enterprise Value: 2.697B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.697B |
| November 20, 2024 | 2.725B |
| November 19, 2024 | 2.654B |
| November 18, 2024 | 2.509B |
| November 15, 2024 | 2.489B |
| November 14, 2024 | 2.501B |
| November 13, 2024 | 2.636B |
| November 12, 2024 | 2.657B |
| November 11, 2024 | 2.701B |
| November 08, 2024 | 2.564B |
| November 07, 2024 | 2.368B |
| November 06, 2024 | 2.269B |
| November 05, 2024 | 2.107B |
| November 04, 2024 | 2.088B |
| November 01, 2024 | 2.070B |
| October 31, 2024 | 2.072B |
| October 30, 2024 | 2.142B |
| October 29, 2024 | 2.156B |
| October 28, 2024 | 2.148B |
| October 25, 2024 | 2.054B |
| October 24, 2024 | 2.010B |
| October 23, 2024 | 1.981B |
| October 22, 2024 | 1.959B |
| October 21, 2024 | 1.927B |
| October 18, 2024 | 1.951B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.902B |
| October 16, 2024 | 1.931B |
| October 15, 2024 | 1.965B |
| October 14, 2024 | 1.972B |
| October 11, 2024 | 1.952B |
| October 10, 2024 | 1.873B |
| October 09, 2024 | 1.916B |
| October 08, 2024 | 1.935B |
| October 07, 2024 | 1.921B |
| October 04, 2024 | 2.034B |
| October 03, 2024 | 1.935B |
| October 02, 2024 | 1.903B |
| October 01, 2024 | 1.871B |
| September 30, 2024 | 1.980B |
| September 27, 2024 | 2.015B |
| September 26, 2024 | 2.058B |
| September 25, 2024 | 2.065B |
| September 24, 2024 | 2.091B |
| September 23, 2024 | 2.171B |
| September 20, 2024 | 2.181B |
| September 19, 2024 | 2.252B |
| September 18, 2024 | 2.170B |
| September 17, 2024 | 2.071B |
| September 16, 2024 | 2.090B |
| September 13, 2024 | 2.147B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
256.14M
Minimum
Mar 18 2020
3.060B
Maximum
Jun 28 2021
1.526B
Average
1.514B
Median
Feb 08 2022
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 2.077B |
| Exelixis Inc | 8.758B |
| Halozyme Therapeutics Inc | 6.652B |
| ADMA Biologics Inc | 5.050B |
| Natera Inc | 21.80B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.901M |
| Revenue (Quarterly) | 57.90M |
| Total Expenses (Quarterly) | 60.37M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 71.93% |
| Profit Margin (Quarterly) | -1.56% |
| Earnings Yield | 0.12% |
| Normalized Earnings Yield | 0.1234 |